Janus Henderson Group PLC Has $85.99 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Janus Henderson Group PLC trimmed its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 8.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,161,544 shares of the medical research company's stock after selling 103,834 shares during the period. Janus Henderson Group PLC owned about 0.20% of Edwards Lifesciences worth $85,992,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Edwards Lifesciences in the fourth quarter worth $610,895,000. Jennison Associates LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $555,939,000. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock worth $314,182,000 after buying an additional 3,506,886 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Edwards Lifesciences during the fourth quarter valued at approximately $213,844,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $70.78, for a total transaction of $796,275.00. Following the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,150,791.86. The trade was a 27.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company's stock, valued at $3,189,770.56. This represents a 16.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,192 shares of company stock worth $4,709,454. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

NYSE:EW traded up $1.04 during mid-day trading on Friday, reaching $77.92. The stock had a trading volume of 4,956,186 shares, compared to its average volume of 5,078,189. The stock has a 50-day simple moving average of $71.89 and a two-hundred day simple moving average of $71.67. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The stock has a market capitalization of $45.71 billion, a PE ratio of 11.18, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.66 EPS. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of analyst reports. Robert W. Baird lifted their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research report on Thursday, April 24th. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Piper Sandler boosted their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $79.60.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.